Cullinan Apollo

Cullinan Apollo is developing VK-2019, an oral EBNA 1 (Epstein-Barr Nuclear Antigen 1) inhibitor. EBV (Epstein-Barr Virus), a well-established driver of various cancers, is critically reliant on the viral DNA-binding factor EBNA1 for viral genome maintenance. VK-2019 potently inhibits EBNA1 function. In preclinical models of EBV-associated cancer, it eliminated EBV, resulting in tumor growth inhibition.